Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

Dianthus Therapeutics (Nasdaq: DNTH) will participate in the TD Cowen 46th Annual Health Care Conference in Boston.

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) will participate in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO, will join an analyst-led fireside chat on March 3, 2026 at 1:50 pm ET and hold one-on-one investor meetings.

A webcast will be available under News and Events in the Investors section of the company's website.

Argus Feb 24 session

+0.34% close to close Open Argus

Details

News Market Reaction – DNTH

On Feb 24, the day this news came out, DNTH closed 0.34% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Market Context

This announcement adds another investor-relations touchpoint, with DNTH’s CEO presenting at a major ...

Analysis

This announcement adds another investor-relations touchpoint, with DNTH’s CEO presenting at a major healthcare conference and offering one-on-one meetings. It follows a series of conferences, a Phase 1 trial initiation, and Q3 2025 results highlighting roughly $525M in cash and ongoing pipeline progress. Investors may track how messaging at these events connects to future clinical milestones, capital deployment under the $600,000,000 shelf, and subsequent SEC disclosures.

Key Figures

Estimated adjusted cash: ~$525M Q3 2025 R&D expense: $32.5M Q3 2025 net loss: $36.8M +5 more

Estimated adjusted cash

~$525M

Q3 2025, per Nov 5, 2025 earnings update

Q3 2025 R&D expense

$32.5M

R&D spending in Q3 2025

Q3 2025 net loss

$36.8M

Net loss in Q3 2025

Shelf registration size

$600,000,000

S-3 shelf filed Jan 28, 2026

Point72 ownership

2,981,674 shares (6.9%)

Beneficial ownership as of Feb 13, 2026

RA Capital ownership

2,611,733 shares (6.0%)

Beneficial ownership as of Dec 31, 2025

Preliminary year-end cash

$514M

Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025

CEO option grant

355,000 options at $52.46

Stock option grant on Feb 3, 2026, 10-year term

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Conference participation

   24h Move

   -3.2%

   Announcement of Guggenheim biotech summit fireside chat and investor meetings.

2. Jan 05

   Conference participation

   24h Move

   -7.0%

   J.P. Morgan Healthcare Conference presentation and one-on-one investor meetings.

3. Dec 23

   Clinical trial start

   24h Move

   -2.6%

   Initiation of Phase 1 trial for LBL-047 (DNTH212) in SLE and volunteers.

4. Nov 24

   Conference participation

   24h Move

   +5.4%

   Evercore healthcare conference fireside chat and investor meetings.

5. Nov 05

   Earnings and updates

   24h Move

   +1.6%

   Q3 2025 results with positive clinical progress and strengthened cash position.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46^th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Dianthus Therapeutics (DNTH) present at the TD Cowen conference in 2026?

Dianthus Therapeutics will present on March 3, 2026 at 1:50 pm ET. According to Dianthus Therapeutics, CEO Marino Garcia will appear in an analyst-led fireside chat and host investor one-on-one meetings at the TD Cowen 46th Annual Health Care Conference.

Who will represent DNTH at the TD Cowen 46th Annual Health Care Conference?

Marino Garcia, CEO of Dianthus Therapeutics, will represent the company at the conference. According to Dianthus Therapeutics, Garcia will take part in an analyst-led fireside chat and conduct one-on-one investor meetings on March 3, 2026.

How can investors watch the DNTH presentation at the TD Cowen conference?

A webcast of the presentation will be available via the company's investor site under News and Events. According to Dianthus Therapeutics, the webcast can be accessed through the Investors section on the Dianthus Therapeutics website.

What topics will DNTH likely cover during the March 3, 2026 fireside chat?

The company will discuss clinical-stage programs and corporate strategy during the fireside chat. According to Dianthus Therapeutics, CEO Marino Garcia will present the company's development focus and meet with investors for follow-up discussions.

Will Dianthus Therapeutics (DNTH) hold investor meetings at the TD Cowen conference?

Yes, DNTH will host one-on-one meetings with investors during the conference. According to Dianthus Therapeutics, Marino Garcia will participate in individual investor meetings in addition to the analyst-led fireside chat on March 3, 2026.

Where and when is the TD Cowen 46th Annual Health Care Conference that DNTH will attend?

The TD Cowen 46th Annual Health Care Conference takes place in Boston, and DNTH will present on March 3, 2026. According to Dianthus Therapeutics, the company will attend the Boston event and offer a webcast for remote investors.